Hydromorphone Injection Recalled for Lack of Sterility Assurance
SCA Pharmaceuticals is recalling 909 syringes of HYDROmorphone HCl 30 mg/30 mL injection nationwide due to lack of assurance of sterility. Patients should not use affected lots and consult their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or hospitalizations. Non-sterile injections present a serious risk of infection, but injury has not yet been reported.
Plain-English summary
SCA Pharmaceuticals is recalling 909 syringes of HYDROmorphone HCl 30 mg/30 mL (1 mg/mL concentration) in 0.9% Sodium Chloride Injection across the United States. The affected product is a prescription injectable opioid medication.
The recall is due to lack of assurance of sterility in the recalled syringes. Non-sterile injections could result in serious infection or other complications when administered.
The affected lots include Lot# 1223048258 (expiration 11/10/23), Lot# 1223048890 (expiration 12/07/23), and Lot# 1223049134 (expiration 12/19/23). The product is manufactured by SCA Pharmaceuticals, LLC (Windsor, CT) and identified by NDC 70004-0303-21.
Healthcare providers and patients currently using affected lots should discontinue use immediately and consult with their healthcare provider.
The recalled product
- Product
- HYDROmorphone HCl 30 mg/30 mL in 0.9% Sodium Chloride Injection, (Concentration = 1mg/mL) 30 mL fill Syringe, Rx only, SCA Pharmaceuticals, 755 Rainbow Rd., Windsor, CT 06095, NDC 70004-0303-21, Bar Code 70004030321
- Manufacturer
- SCA Pharmaceuticals, LLC
- Category
- Drug — Injectable Opioid
- Hazard
- lack-of-sterility
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot#: 1223048258 Exp 11/10/23
- 1223048890 Exp 12/07/23
- 1223049134 Exp 12/19/23
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27